[Angioid streaks complicated by choroidal neovascularization secondary to pseudoxanthoma elasticum: diagnosis and treatment. Case report].
Angioid streaks represent linear breaks in Bruch's membrane secondary to a change in the elastic layer. They are often associated with pseudoxanthoma elasticum. We report the case of a 36-year-old man with no prior history who was seen for a macular problem in the left eye, eventually involving the right eye after 3 months. He was diagnosed with pseudoxanthoma elasticum, associated with angioid streaks, complicated by choroidal neovascularization in both eyes. He was treated with intravitreal ranibizumab injections (0.5 mg/0.05 mL). His course in the right eye was remarkable for stable improvement at 3 months after the final injection. In the left eye, after initial improvement, recurrence was noted 2.5 months after injection, with subfoveal progression of the choroidal neovascularisation, unresponsive to a fourth ranibizumab injection. Angioid streaks represent a degenerative retinal pathology of elastic tissue with the potential for ingrowth of choroidal neovascularization. Various therapeutic approaches such as photodynamic therapy or laser photocoagulation have been proposed, with variable and sometimes limited results. Intravitreal ranibizumab injections currently remain the best treatment and should be studied with a longer-term, larger series.
Hôpital militaire de Tunis, 1008 Montfleury, Tunis, Tunisie. afefmaalej@yahoo.fr
A
A
Maalej
M
M
Ouederni
A
A
Khallouli
S
S
Gabsi
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000793:Angioid Streaks / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D020256:Choroidal Neovascularization / Q000150:complications* / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D011561:Pseudoxanthoma Elasticum / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D000069579:Ranibizumab
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab